{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030873","form_type":"8-K","ticker":"NRXS","cik":"0001933567","company_name":"Neuraxis, INC","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.222417+00:00","generated_at":"2026-05-31T10:33:18.351923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeurAxis Q2 revenue down 5.3% to $611.5K; net loss widens to $2.9M; insurance coverage expands to 22.5M lives","bullets":["Revenue $611.5K, down 5.3% YoY; gross margin 88.0% vs 89.5%.","Net loss $2.9M, up 30.5% YoY; operating loss $2.2M, up 97.5%.","Covered lives grew to 22.5M from 4.5M a year ago; commitment from payer with 12M lives starting Oct 1.","Submitted RED device to FDA for clearance expected Q4 2024; submitted label expansion to ages 8-21.","Secured additional $3.0M funding in May; total committed financing $9.1M; cash $1.8M, short-term debt $4.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030873","json":"https://secwatch.observer/filing/0001493152-24-030873.json","markdown":"https://secwatch.observer/filing/0001493152-24-030873.md","text":"https://secwatch.observer/filing/0001493152-24-030873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933567/000149315224030873/0001493152-24-030873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933567/000149315224030873/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:33:18.351923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}